2017 年度十大中国医学科技新闻揭晓，分别是：1、人类胚胎发育机制研究取得新进展；2、重组埃博拉病毒疫苗获批；3、肝癌T细胞免疫图谱被绘制；4、中国新药从仿制走向创新；5、全流程发力加快我国新药研发生产上市；6、基因编辑“制动装置”被破译；7、新型双光子荧光显微镜问世；8、噻托溴铵治疗早期慢阻肺安全有效；9、首个

The 2nd International Conference on Clinical & CellularImmunology... and others in a commonendeavor.with a theme to “Disseminating new trends

of Treatment of tuberculosis: guidelines, adhering fully to the new WHO proc-ess&nbsp...; recommendations are beingpromoted in this new edition.First

Obesity and Type 2 Diabetes associate with a disruption in energy, glucose and lipid homeostasis. New exciting developments continue to indicate a key role

文章 1：New Assay for Old markers-Plasma Beta Amyloid of Mild Cognitive Impairment and Alzheimer’s Disease检测轻度认知障碍和阿尔茨海默病患者血浆β-淀粉样蛋白的新方式文章 2：Plasma levels

In the 2 years since the publication of the 2007 guidelines... been pursued and the results of new important studies (including several large

2019 CPhI Menet Summit Forum : China New Drug Research and Development Summit...Hall E2 M17 Meeting RoomE2 馆 M17 会议室外部环境变化已经充分反映出国内医药产业升级的迫切性，同时国内多项政策措施的鼓励也共同刺激国内

9月19日消息 - 前沿医学资讯网据悉，据加州大学洛杉矶分校（UCLA）进行的一项新的研究，两种用于治疗2型糖尿病的新药与胰腺炎和胰腺癌风险显著增加相关...胰腺癌风险。西他列汀和艾塞那肽为增强肠道激素胰高血糖素样肽1（GLP-1）作用的药物，已显示可有效降低2型糖尿病患者的血糖水平。先前

or type 2 diabetes, and an additional 480 000 (1.4%) were unaware that they were... with newly diagnosed diabetes were 45–64 years old (Figure 2). Substantial

, and Chinese Medical Board (New York) Award of Outstanding Young Scholars. 幻灯片

使用说明：Visistar VEGFR2是一种表面偶联VEGFR2（血管内皮生长因子受体-2）抗体的靶向超声造影剂，可特异性结合血管内皮细胞表面的VEGFR2受体。本产品在超声波频率为1-20MHz范围内可以达到最佳的回声增强，也可应用于频率为20-40MHz的超高频成像。在超声显影时，应将超声模式设置为CPS

Type 2 Diabetes Prevention-1Diabetes Prevention Program (DPP)-2DPP Participants-3DPP

Glycemic management in type 2 diabetes mellitus has become increasingly... and new uncertainties regarding the benefits of intensive glycemic control

议题/演讲人主持人4th of Mar. 2

2. 重组埃博拉病毒病疫苗获批3. 肝癌T细胞免疫图谱成功绘制4. 中国新药从仿制走向创制5. 全流程发力加快我国新药研发...; 195个国家和地区调查揭示全球健康三大变化2. 肺是重要造血器官3. RNA编辑技术展示广阔前景

Breast cancer screening remains a subject of intense and, at times, passionate debate. Mammography has long been the mainstay of breast cancer detection and is the only screening test proven to reduce mortality. Although it remains the gold standard of breast cancer screening, there is increasing awareness of subpopulations of women for whom mammography has reduced sensitivity. Mammography also has undergone increased scrutiny for false positives and excessive biopsies, which increase radiation dose, cost, and patient anxiety. In response to these challenges, new technologies for breast cancer screening have been developed, including low-dose mammography, contrast-enhanced mammography, tomosynthesis, automated whole breast ultrasound, molecular imaging, and magnetic resonance imaging. Here we examine some of the current controversies and promising new technologies that may improve detection of breast cancer both in the general population and in high-risk groups, such as women with dense breasts. We propose that optimal breast cancer screening will ultimately require a personalized approach based on metrics of cancer risk with selective application of specific screening technologies best suited to the individual\\\'s age, risk, and breast density